Open an account

BG Medicine

BGMD · OTC

$0.00−$0.0001 (−99.00%)TodayMarket closed ·
No price history for this range.

About BGMD

BG Medicine, Inc. is a life sciences company, which engages in the provision of developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The company is headquartered in Waltham, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2011-02-04. The firm is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The firm's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The firm's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Employees
5
Headquarters
Waltham, Massachusetts
Listed
Feb 4, 2011
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
bg-medicine.com

BGMD key statistics

Market cap
11
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
2.22K
Volume
50
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

BG Medicine (BGMD) at a glance

As of Oct 9, 2026, BG Medicine (BGMD) shares are priced at $0.00, giving the company a market cap of 11 and a price-to-earnings ratio of 0.00.

Volume so far is 50 shares, below the average of 2.22K shares a day.

Over the past year BG Medicine has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

BG Medicine met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q4 FY14 it reported -$0.16 per share against an estimate of -$0.204.

BGMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 18.5% on average.

  1. Q1 FY13: reported -$0.84 per share against an estimate of -$1.08
  2. Q2 FY13: reported -$0.72 per share against an estimate of -$0.8024
  3. Q3 FY13: reported -$0.52 per share against an estimate of -$0.6732
  4. Q4 FY13: reported -$0.24 per share against an estimate of -$0.4896
  5. Q1 FY14: reported -$0.32 per share against an estimate of -$0.3264
  6. Q2 FY14: reported -$0.24 per share against an estimate of -$0.2448
  7. Q3 FY14: reported -$0.24 per share against an estimate of -$0.2856
  8. Q4 FY14: reported -$0.16 per share against an estimate of -$0.204

Similar companies

Companies in the same industry as BG Medicine

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.